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The National Cancer Data Base (NCDB) is a
nationwide oncology outcomes database that cur-
rently collects information on approximately 70% of
all new invasive cancer diagnoses in the United States
each year and serves as a powerful clinical surveil-
lance and quality improvement mechanism for cancer
programs participating in the American College of
Surgeons (ACoS) Commission on Cancer (CoC)
approvals program.
1–3 Currently, the NCDB receives
over one million cancer case reports annually from
more than 1,430 hospitals. The NCDB now contains
data on more than 21 million cancer patients diag-
nosed between 1985 and 2005, and is recognized as
the largest clinical registry in the world. NCDB data
are used to explore trends in cancer care, to examine
regional and national benchmarks, and to serve as
the basis for quality improvement activities (
http://www.facs.org/cancer/ncdb)
The purposes of this review are: (1) to describe the
NCDB and the data collected; (2) to discuss how the
NCDB can be used to study clinical outcomes and the
quality of cancer care in the United States; and (3) to
describe the clinical care improvement tools provided
by the NCDB and the CoC to participating hospitals.
BACKGROUND: THE COMMISSION ON
CANCER AND THE NCDB
The CoC is a multidisciplinary consortium of
professional organizations that strive to improve
cancer care through setting standards, prevention,
research, education, and the monitoring of compre-
hensive cancer care.
4 The CoC also accredits hospi-
tals as cancer centers, based on their ability to
provide a broad range of cancer-related services and
specialists.
2 The NCDB was started in 1989 by the
ACoS and the CoC in conjunction with the American
Cancer Society. The NCDB is housed at the ACoS
headquarters in Chicago, Illinois. When the database
was established any hospital could voluntarily report
data to the NCDB, and during the mid 1990s, more
than 2,000 hospitals were contributing cases. In 1996,
all CoC-approved hospitals were required to report
cancer cases to the NCDB, and in 2001, participation
and the associated advantages of reporting to the
NCDB were limited to those hospitals who had
earned CoC approval.
5
PARTICIPATING HOSPITALS
The CoC classiﬁes approved hospitals into teach-
ing/research hospitals, comprehensive community
cancer centers, and community cancer centers.
2
Teaching/research hospitals must be primarily afﬁli-
ated with a medical school or National Cancer
Institute (NCI)-designated comprehensive cancer
center. Community cancer center designations are
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683based on a combination of annual case volume and
the ability to provide a wide range of cancer-speciﬁc
personnel and services. Of the 1,430 hospitals that
report to the NCDB, approximately 20% are classi-
ﬁed as teaching/research hospitals, 39% are compre-
hensive community cancer centers, 35% are
community cancer centers, and 6% are other cancer
centers that include Veterans Health Administration
(VA) hospitals (Fig. 1).
Reporting hospitals are located in 49 US states and
also Puerto Rico. The cancer programs that report to
the NCDB include 19 of 20 adult National Com-
prehensive Cancer Network (NCCN) hospitals, 33 of
37 NCI-designated cancer centers, and 69 of 121
major inpatient VA hospitals. Some hospitals may
elect not to gain CoC approval and thus not con-
tribute data to the NCDB, but the reasons for this are
unclear. The 1,430 hospitals that have approved
cancer programs and report data to the NCDB ac-
count for approximately one third of the inpatient
hospitals in the United States. While the NCDB does
collect the majority of incident cases in the United
States, a hospital selection bias may exist as only
CoC-approved hospitals contribute data to the
NCDB.
HOW CASES ARE REPORTED
In 1973 federal legislation made invasive cancer a
reportable disease, and in 1992 federal legislation
further mandated that all cancer cases be reported to
state cancer registries.
6 The CoC requires its ap-
proved programs to abstract and follow all malignant
tumors diagnosed and/or initially treated at the hos-
pital.
7 Annually, CoC-approved hospitals report over
one million cancer cases to the NCDB. Approxi-
mately 940,000 cases are new invasive cancer diag-
noses and account for about 70% of all new cancer
diagnoses in the United States, based on annual
incidence estimates from the American Cancer Soci-
ety (Table 1).
8 In addition, the NCDB takes receipt
of over 50,000 in situ cancers and 18,000 benign and
borderline brain and central nervous system tumors.
Patients diagnosed and treated in a physicians ofﬁce
setting, those who undergo consultation to conﬁrm a
diagnosis or formulate a treatment plan, and cases
reviewed by pathology, but who never enter the
hospital for any aspect of their care, are not reported
to the NCDB.
Data reporting to the NCDB is highly standard-
ized and similar to other state health departments
and federal cancer registry data systems, including
the NCIs Surveillance Epidemiology and End Re-
sults (SEER) program and the Centers for Disease
Controls National Program of Cancer Registries
(NPCR).
9,10 Data reported from CoC-approved
hospitals are abstracted from patient charts by
Certiﬁed Tumor Registrars (CTR) who undergo
training speciﬁc to cancer registry operations.
11 In
recent years, the training and certiﬁcation require-
ments for CTRs have increased signiﬁcantly, focus-
ing on many of the nuances of cancer care. If data
points are missing, registrars can query the treating
physicians to obtain the necessary data to complete
the record.
All data submitted to the NCDB undergo a battery
of data integrity checks.
12 The rigor of these data
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FIG. 1. Percentage distribution of
the type of hospitals that report to
the NCDB and the percentage of
cases contributed by each hospital
to the NCDB for 2005. NCDB,
National Cancer Data Base.
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cantly for the diagnosis year 2002 and expanded
further for 2005 diagnoses. Case records that fail to
meet a standardized set of requirements are identiﬁed
and returned to the hospital. Internal studies com-
paring the quality of data reporting from large
teaching/research hospitals and small community
centers revealed no distinct differences in the com-
pleteness or accuracy of reported data.
13
Each year, the NCDB undergoes extensive internal
quality monitoring and validity reviews. Aggregate
data are examined and veriﬁed in advance of the re-
lease of annual reports created for each cancer site,
and the release of data for analytic purposes.
14 In
addition to these extensive automated electronic
data-quality checks, site surveyors from the CoC
evaluate each hospitals data and data-collection
processes once every three years, to ensure that high-
quality case information is being reported to the
NCDB in an accurate and timely fashion. The NCDB
has also undergone multiple data-quality re-
views.
15–18
Once diagnosed and/or treated at a hospital with a
CoC-approved cancer program, the patient will be
followed by the hospital registrar and the case will be
reported to the NCDB regardless of whether the
patient receives part of their care at a non-CoC
hospital. For example, a patient is diagnosed with a
malignancy at hospital A which does not report to
the NCDB, undergoes surgery at hospital B which
reports to the NCDB, and then returns to hospital A
for adjuvant therapy. The CoC requires that the
cancer registry at hospital B record the information
regarding diagnosis from hospital A and enter follow-
up data from hospital A regarding subsequent treat-
ment, recurrence, and survival (active surveillance). If
both hospitals were CoC approved, two case records
for the same patient would be reported to the NCDB,
termed a ,clinical duplicate. These duplicate cases are
identiﬁed using a computer algorithm, and the case
TABLE 1. Proportion of invasive cancers in the United States reported to the NCDB in 2005 by organ site
Cancer Site
Number of invasive
malignancies reported
to the NCDB
Estimated number of
annual cancer cases in
the United States
1
Proportion of invasive
malignancies reported
to the NCDB
Anus 3,476 3,990 87.1%
Bladder
2 40,647 63,210 64.3%
Bones and joints 2,178 2,570 84.7%
Breast 141,741 212,930 66.6%
Cervix 9,912 10,370 95.6%
Colon 65,576 104,950 62.5%
Esophagus 11,296 14,520 77.8%
Gallbladder and other biliary 6,205 7,480 83.0%
Kidney, renal pelvis, ureter 33,513 38,670 86.7%
Larynx 9,541 9,880 96.6%
Leukemia 20,366 34,810 58.5%
Liver and intrahepatic bile ducts 11,440 17,550 65.2%
Lung and bronchus 141,757 172,570 82.1%
Lymphoma 54,034 63,740 84.8%
Melanoma 28,865 59,580 48.4%
Oral cavity and pharynx 23,824 29,370 81.1%
Other sites 64,503 88,610 72.8%
Ovary 15,225 22,220 68.5%
Pancreas 23,724 32,180 73.7%
Prostate 117,995 232,090 50.8%
Rectum 30,676 40,340 76.0%
Small intestine 4,001 5,420 73.8%
Soft tissue 7,350 9,420 78.0%
Stomach 13,882 21,860 63.5%
Testis 5,729 8,010 71.5%
Thyroid 23,648 25,690 92.1%
Uterus 30,571 40,880 74.8%
TOTAL 941,675 1,372,910 68.6%
1 Estimated number of invasive malignancies in the United States for 2005 based American Cancer Society estimates.
63 The American
Cancer Society has since revised their estimation methodology by basing their calculations on data from state cancer registries rather than on
SEER regions. Estimates of cancer incidence have increased with this new methodology.
2 American Cancer Society estimates for bladder cancer include in situ disease.
Note: The NCDB requires reporting of all in situ cancers for most cancer sites; however, these are not included in the table above. For 2005
diagnoses, more than 50,000 in situ malignancies were reported to the NCDB. The NCDB also receives benign, as well as malignant, brain
tumors.
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in the analytic dataset.
DATA ITEMS COLLECTED
The NCDB collects data on patient factors, tumor
characteristics, staging details, surgical and adjuvant
treatments, and outcomes, using nationally stan-
dardized coding guidelines.
19 All CoC- approved
hospitals submitting data to the NCDB are required
to use the Facility Oncology Registry Data Standards
(FORDS) manual to guide abstracting and coding.
7
Additional guidelines for coding histopathological
characteristics and stage of disease are established by
the World Health Organization (WHO) in its Inter-
national Classiﬁcation of Disease for Oncology
(ICD-O) and the American Joint Committee on
Cancer (AJCC), respectively.
20,21
Tumor characteristics include size, the presence
and location of nodal and distant metastases, number
of nodes positive and examined, grade, margin status,
and both clinical and pathological staging informa-
tion. Clinical stage is a pretreatment assessment that
is recorded prior to surgery, and if the patient
undergoes resection, a pathological stage is recorded
separately. Beginning with cases diagnosed in 2004,
the NCDB started collecting Collaborative Stage
data elements, in addition to physician-recorded
AJCC clinical and pathological tumor–node–metas-
tasis (TNM) elements and overall stage. For the
purpose of assessing comorbidity, the International
Classification of Disease, 9
th Edition (ICD-9-CM),
secondary diagnosis codes, excluding cancer diagno-
ses and post-operative complications, are recorded
for each patient.
The NCDB also collects a wide range of data
regarding surgical treatment and adjuvant therapy,
including radiation, chemotherapy, hormone ther-
apy, and other systemic treatments. Patients are also
followed to assess outcomes including readmission
within 30 days, recurrence, and survival. CoC-ap-
proved hospitals are expected to provide follow-up
on at least 90% of all known living patients annually.
Through linkage to tertiary data sources, area-
based socioeconomic status and estimates of travel
distance/time to the reporting hospital can be ob-
tained based on each patients home zip code at the
time of diagnosis. In addition, hospital type and
structural characteristics can be determined through
linkage with the CoCs facility information proﬁle
system (FIPS) ﬁle of self-reported hospital structural
features, resources, and services related to oncology.
4
DATA CONFIDENTIALITY
The ACoS and the NCDB take great care to pro-
tect patient and hospital anonymity. The American
College of Surgeons has a business associate agree-
ment with each of its CoC-approved hospitals that
prohibits the CoC from revealing hospital-speciﬁc
information. Data reported to the NCDB are retro-
spective in nature. No direct patient identiﬁers are
collected. Analyses are reported only at the aggregate
level to assist hospital cancer programs with quality
assurance and improvement. Reported results are in
compliance with the privacy requirements of the
Health Insurance Portability and Accountability Act
(HIPAA).
22
CLINICAL OUTCOMES STUDIES
The NCDB oﬀers a large, nationally applicable
sample to examine oncology practice patterns and
outcomes in the United States. Single institutions
studies are typically from large centers that focus on
particular malignancies. With information from a
wide range of hospitals in diverse geographic loca-
tions, a better understanding of the variability in care
across the country can be analyzed, and, in particu-
lar, smaller, non-specialty hospitals can be examined
in order to compare diﬀerences by hospital type and
volume of patients. This is particularly important
since the majority of cancer patients in the United
States are not treated at high-volume, specialized
centers.
Initially, the large number of patients available for
analysis through the NCDB resulted in a consider-
able body of descriptive literature on the clinical and
epidemiologic characteristics of common cancers in
the United States.
23 Subsequent studies have been
more hypothesis driven and have addressed a broad
range of cancers and oncological issues. Several
studies have used the NCDB to examine surgical and
adjuvant therapy treatment trends and utiliza-
tion.
24–32 The large sample size offered by the NCDB
allows studies of rare cancers (i.e., pancreatic neuro-
endocrine tumors, metaplastic breast cancer, and
melanoma in children)
33–38 and subset analyses (i.e.,
stage I pancreatic cancer patients undergoing resec-
tion, 1–2 cm papillary thyroid cancers, T3N0 colon
cancer patients)
27,30,39–42 with sufﬁcient statistical
power to make reasonable inferences. As AJCC
staging information is collected, numerous reports
have validated staging systems, and the AJCC has
relied heavily on the NCDB to provide data for the
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modiﬁcations.
21,42–46 Furthermore, studies using
NCDB data have addressed important clinical ques-
tions in areas where clinical trials may be challenging
(i.e., local excision of rectal tumors, and extent of
surgery for papillary thyroid cancer).
27,47
The broad range of hospital types reporting to the
NCDB have also facilitated an array of health ser-
vices research. The NCDB has been used to compare
diﬀerences in treatment and outcome by hospital type
and volume of patients.
25,39,48–50 Data from the
NCDB have also been used to examine concordance
with established quality measures and standards of
clinical care.
26,30,48,51 Multiple studies have also
examined cancer care for minorities and disadvan-
taged populations,
52–54 and a recent article examined
how clinical trials could be developed to speciﬁcally
target minority populations.
55 Statistical methodol-
ogy pertaining to outcomes research has also been
examined for multiple cancer sites.
56 In addition, the
NCDB can be used to obtain details beyond those
typically collected, by requiring cancer registrars to
ascertain additional data points on a speciﬁc cohort
of patients.
27,50,51,57
Although there are limitations associated with the
use of cancer registry data, appropriate, hypothesis-
driven questions can be eﬀectively investigated.
58
Administrative datasets are based on data with
ﬁnancial motivations, such as claims or reimburse-
ment, whereas cancer registries are designed and
collect data with the intent of studying cancer epi-
demiology, treatment trends and utilization, out-
comes, and the quality of cancer care. In addition,
cautious investigations regarding the efﬁcacy of
treatments can also be examined.
27,59 Results from
these studies are useful and important in order to
generate hypotheses for future prospective studies
and clinical trials.
QUALITY IMPROVEMENT
Although the NCDB is a tremendous repository of
oncologic data, perhaps the most important aspect is
its ability to benchmark hospitals, and feed infor-
mation back to the public and to participating hos-
pitals. The NCDB oﬀers public benchmark reports
for the eleven most commonly diagnosed solid-organ
tumors in the United States.
14 These reports currently
provide data on more than 5.9 million patients,
allowing users to deﬁne queries based on patient
gender, age, ethnicity, histology, stage, ﬁrst-course
therapy, type of surgical resection, hospital type, and
geographic location. The NCDB also offers ﬁve-year
survival reports stratiﬁed by AJCC staging.
60
In early 2007, the National Quality Forum (NQF)
endorsed ﬁve quality measures developed in a joint
eﬀort between the ACoS, the National Comprehen-
sive Cancer Network (NCCN), and the American
Society of Clinical Oncology (ASCO).
61,62 Four of
these measures focus on adjuvant therapy for breast
and colorectal cancer, and one measure concerns the
resection and pathological examination of 12 or more
regional lymph nodes for colon cancer. Hospitals
with CoC-approved cancer programs reporting to the
NCDB are evaluated and benchmarked according to
their performance on these measures. Hospitals can
examine their performance on each measure in com-
parison to the other 1,430 CoC hospitals, allowing
only the reporting hospital to see where they rank in
comparison to the rest of the state, region, or country
(Fig. 2). Moreover, this data feedback mechanism
allows hospitals to evaluate deﬁcient records, to en-
sure the accuracy and completeness of their data, and
make corrections and additions as needed.
These quality-of-care reports are intended to pro-
vide hospitals with the ability to measure and com-
pare standards of cancer care at their facility to that
of a large number of hospitals across the country,
without any associated accountability. Over the next
year, the NCDB will be developing and incorporating
additional quality measures for multiple cancers,
including common (i.e., lung) and complex (i.e.,
pancreas) malignancies.
FUTURE DIRECTIONS
The power of the NCDB clearly rests in its ability
to receive data, analyze it, and send actionable
information back to hospitals for the purposes of
quality improvement. These quality improvement
activities will play a signiﬁcant role in the future for
the NCDB. In addition to the breast and colorectal
initiatives, quality measures must be developed for
other cancer sites. These measures should not be used
for accountability, but rather only to provide infor-
mation to hospitals with the aim of improving patient
care and outcomes. In the future, federal regulatory
agencies, payers, purchasers, and consumers may
look to data from cancer registries to assess surgical
quality, determine reimbursement levels, and judge
providers on the basis of process measures and pa-
tient outcomes.
The NCDB will soon have a de-identiﬁed dataset
available to investigators at CoC-approved hospitals.
THE NATIONAL CANCER DATA BASE 687
Ann. Surg. Oncol. Vol. 15, No. 3, 2008This ﬁle will provide the opportunity to examine a
large dataset containing a number of data items that
are not available through other cancer registries
including surgical margin status, systemic therapy
(chemotherapy and hormonal therapy), detailed
radiation treatment data, and clinical and patholog-
ical AJCC staging.
CONCLUSIONS
The NCDB is a large, powerful database pro-
viding multiple opportunities for clinical studies and
quality-improvement endeavors. Importantly, the
NCDB can be used to benchmark hospitals on
performance measures and serve as an impetus for
quality improvement initiatives at the hospital level.
Cancer registration activities are expensive for hos-
pitals, but the beneﬁts are clearly demonstrated by
the NCDBs extensive eﬀorts to feed important
information back to participating institutions. The
NCDB is the only cancer registry that provides
feedback data to hospitals in such a manner. It is
the responsibility of surgeons, and their colleagues
in other oncologic specialties, to work collectively,
and with their hospitals cancer registrars, to con-
tinuously review and improve the accuracy, com-
pleteness and quality of the hospitals cancer
registry data, and thus the quality of the data re-
ported to the NCDB. The NCDB is a valuable tool
to improve the quality of cancer care in the United
States.
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